WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR April 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: APRIL ISSUE PUBLISHED

    APRIL 2024 Issue has been successfully launched on APRIL 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

PREGNANCY INDUCED HYPERTENSION (PIH): A REVIEW

Nighat Saleh, Rahman Gul*, Safia Mengal, Kashmala Khan, Falsafa Jamal, Mir Abdul Qadir, Abdul Ghani Sasoli, Muhammad Zaman Khethran and Aida durrani

ABSTRACT

Almost 6-10% of pregnancies develop complications if mother become hypertensive during pregnancy, this is known as Pregnancy induced hypertension (PIH) in which blood pressure becomes higher than normal i.e., >140/90 mmHg. PIH classified in Mild, Moderate and Sever hypertension according to the blood pressure levels Mild BP 140–149/90–99 mmHg, Moderate BP 150–159/100–109 mmHg, and Severe BP> 160/110 mmHg are the three categories. some conditions related to pregnancy induced hypertension like chronic hypertension, pregnancy induced hypertension and pre-eclampsia, chronic hypertension with superimposed pregnancy induced hypertension plus proteinuria and unclassified hypertension. Pregnancy induced hypertension play a big role in hazards for mother, fetus and newborn morbidity and mortality. PIH have lethal effects on both the mother who have a greater risk of suffering from abruptio placentae, cerebrovascular disturbances e.g. (cerebral oedema, hyper perfusions), organ failure and disseminated intravascular coagulation And on Fetus as growth retardation (IUGR), premature and still births. after 24 h monitoring of ambulatory BP it appears as having a part in the decline from pregnancy induced hypertension to Preeclampsia. antithrombin medicines show good preventive effects in Pre-eclampsia. different Therapy is based on blood pressure readings, gestational age, symptoms, and risk factors. Consider non-drug management when blood pressure is between 140 and 149/90 and 99 mmHg. health organizations recommended different treatment line in pregnancy according to the blood pressure levels Antihypertensive therapy is recommended in accordance with the 2013 ESH/ESC guidelines. when a woman is pregnant and her blood pressure is 150/95 mmHg. treatment should start to female 140/90 mmHg BP plus pregnancy induced hypertension+/- proteinuria, persistent high blood pressure with superimposition of PIH or high bp with organ damage or impairment without symptoms in any trimester. The medication of choice during pregnancy is methyldopa. While labetalol has an efficacy similar to methyldopa In late pregnancy, metoprolol and atenolol seem to be both safe and helpful medications. Due to their harmful effects on the fetus, ACE inhibitors and angiotensin II antagonists are not allowed to be taken during pregnancy.

[Full Text Article] [Download Certificate]